Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with a dose response

Next Previous
Trial Profile

A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with a dose response

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Dupuytren's contracture
  • Focus Pharmacodynamics; Proof of concept; Registrational
  • Acronyms RIDD

Most Recent Events

  • 03 Aug 2023 According to a 180 Life Sciences media release, the company has submitted a request to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for a follow up scientific advice meeting. A meeting with the MHRA is anticipated to take place in late Q3 of 2023 with the written responses anticipated to be received prior to year end.
  • 25 Jan 2023 According to a 180 Life Sciences media release, the company announces publication of review article in The Journal of Hand Surgery (European Volume), which contains this study results.
  • 25 Jan 2023 Results published in the 180 Life Sciences media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top